Biomarkers in Hemophilia: Diagnostic, Prognostic, and Treatment-Selection Utility: A Narrative Review of the Literature
ASIDE Internal Medicine · 2026
DOI: 10.71079/aside.im.022826376 ↗Kurz gefasst
Fachartikel in der Zeitschrift ASIDE Internal Medicine, 2026. Verfasst von Dalia Atef Abouda und 8 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Hemophilia A and B are inherited bleeding disorders in which outcomes are shaped by factor levels, inhibitor development, inter-individual pharmacokinetics, and progressive joint disease. With the emergence of extended half-life therapies, non-factor therapies, and gene therapy, there is an increasing need for biomarkers to support diagnosis, risk stratification, treatment selection, and monitoring.
Methods
We conducted a narrative review of English-language studies indexed in PubMed, Scopus, Web of Science, and Google Scholar (January 2000 to October 2025). We prioritized primary studies, trials, registries, and assay-validation reports on diagnostic, prognostic, predictive, or monitoring biomarkers in hemophilia A/B; guidelines were used for context.
Results
Established biomarkers include FVIII/FIX activity assays, inhibitor testing (Bethesda/Nijmegen-modified), F8/F9 genotyping, and imaging-based joint assessment. Emerging candidates include global hemostasis assays (thrombin generation, viscoelastic testing), PK/PD metrics for prophylaxis individualization, and exploratory inflammatory/angiogenic and tissue-turnover markers linked to arthropathy.
Conclusions
Evidence for biomarkers in hemophilia is heterogeneous, and many non-traditional markers remain exploratory; standardized assays and prospective multicenter validation with clinically meaningful endpoints are needed before routine adoption. Limitation: This narrative synthesis was conducted in English and did not include a formal risk-of-bias assessment.
Zitieren
APA
Abouda, D. A., Moubarak, E. S., ElBadrawy, F., Hassan, M. A., Helal, M. M., Ibrahim, A. M., Eladl, H. H., Mahadin, M., & Elsaid, M. (2026). Biomarkers in Hemophilia: Diagnostic, Prognostic, and Treatment-Selection Utility: A Narrative Review of the Literature. ASIDE Internal Medicine. https://doi.org/10.71079/aside.im.022826376
Vancouver
Abouda DA, Moubarak ES, ElBadrawy F, Hassan MA, Helal MM, Ibrahim AM, et al. Biomarkers in Hemophilia: Diagnostic, Prognostic, and Treatment-Selection Utility: A Narrative Review of the Literature. ASIDE Internal Medicine. 2026. doi:10.71079/aside.im.022826376
BibTeX
@article{Abouda2026,
author = {Abouda, Dalia Atef and Moubarak, Elsayed S. and ElBadrawy, Fatma and Hassan, Malak A. and Helal, Mohamed Mohsen and Ibrahim, Abdallah M. and Eladl, Hassan H. and Mahadin, Mohammad and Elsaid, Mohamed},
title = {Biomarkers in Hemophilia: Diagnostic, Prognostic, and Treatment-Selection Utility: A Narrative Review of the Literature},
journal = {ASIDE Internal Medicine},
year = {2026},
doi = {10.71079/aside.im.022826376}
}
EUVIMED